Literature DB >> 23429540

Quiescent innate response to infective filariae by human Langerhans cells suggests a strategy of immune evasion.

Alexis Boyd1, Sasisekhar Bennuru, Yuanyuan Wang, Vivornpun Sanprasert, Melissa Law, Damien Chaussabel, Thomas B Nutman, Roshanak Tolouei Semnani.   

Abstract

Filarial infection is initiated by mosquito-derived third-stage larvae (L3) deposited on the skin that transit through the epidermis, which contains Langerhans cells (LC) and keratinocytes (KC), among other cells. This earliest interaction between L3 and the LC likely conditions the priming of the immune system to the parasite. To determine the nature of this interaction, human LC (langerin(+) E-cadherin(+) CD1a(+)) were generated in vitro and exposed to live L3. LC exposed to live L3 for 48 h showed no alterations in the cell surface markers CD14, CD86, CD83, CD207, E-cadherin, CD80, CD40, and HLA-DR or in mRNA expression of inflammation-associated genes, such as those for interleukin 18 (IL-18), IL-18BP, and caspase 1. In contrast to L3, live tachyzoites of Toxoplasma gondii, an intracellular parasite, induced production of CXCL9, IP-10, and IL-6 in LC. Furthermore, preexposure of LC to L3 did not alter Toll-like receptor 3 (TLR3)- or TLR4-mediated expression of the proinflammatory cytokines IL-1β, gamma interferon (IFN-γ), IL-6, or IL-10. Interestingly, cocultures of KC and LC produced significantly more IL-18, IL-1α, and IL-8 than did cultures of LC alone, although exposure of the cocultures to live L3 did not result in altered cytokine production. Microarray examination of ex vivo LC from skin blisters that were exposed to live L3 also showed few significant changes in gene expression compared with unexposed blisters, further underscoring the relatively muted response of LC to L3. Our data suggest that failure by LC to initiate an inflammatory response to the invasive stage of filarial parasites may be a strategy for immune evasion by the filarial parasite.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23429540      PMCID: PMC3648007          DOI: 10.1128/IAI.01301-12

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  35 in total

1.  IP-10 is critical for effector T cell trafficking and host survival in Toxoplasma gondii infection.

Authors:  I A Khan; J A MacLean; F S Lee; L Casciotti; E DeHaan; J D Schwartzman; A D Luster
Journal:  Immunity       Date:  2000-05       Impact factor: 31.745

2.  Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis.

Authors:  E von Stebut; Y Belkaid; B V Nguyen; M Cushing; D L Sacks; M C Udey
Journal:  Eur J Immunol       Date:  2000-12       Impact factor: 5.532

Review 3.  Changing views of the role of Langerhans cells.

Authors:  Nikolaus Romani; Patrick M Brunner; Georg Stingl
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

4.  Langerhans cells are precommitted to immune tolerance induction.

Authors:  Elena Shklovskaya; Brendan J O'Sullivan; Lai Guan Ng; Ben Roediger; Ranjeny Thomas; Wolfgang Weninger; Barbara Fazekas de St Groth
Journal:  Proc Natl Acad Sci U S A       Date:  2011-10-17       Impact factor: 11.205

5.  Langerin, the "Catcher in the Rye": an important receptor for pathogens on Langerhans cells.

Authors:  Patrizia Stoitzner; Nikolaus Romani
Journal:  Eur J Immunol       Date:  2011-09       Impact factor: 5.532

6.  Characterization of carbohydrate recognition by langerin, a C-type lectin of Langerhans cells.

Authors:  Nicola S Stambach; Maureen E Taylor
Journal:  Glycobiology       Date:  2003-01-22       Impact factor: 4.313

7.  Stage-specific proteomic expression patterns of the human filarial parasite Brugia malayi and its endosymbiont Wolbachia.

Authors:  Sasisekhar Bennuru; Zhaojing Meng; José M C Ribeiro; Roshanak Tolouei Semnani; Elodie Ghedin; King Chan; David A Lucas; Timothy D Veenstra; Thomas B Nutman
Journal:  Proc Natl Acad Sci U S A       Date:  2011-05-23       Impact factor: 11.205

8.  Interleukin (IL)-18 induces Langerhans cell migration by a tumour necrosis factor-alpha- and IL-1beta-dependent mechanism.

Authors:  M Cumberbatch; R J Dearman; C Antonopoulos; R W Groves; I Kimber
Journal:  Immunology       Date:  2001-03       Impact factor: 7.397

9.  Langerhans cells are negative regulators of the anti-Leishmania response.

Authors:  Kordula Kautz-Neu; Madelon Noordegraaf; Stephanie Dinges; Clare L Bennett; Dominik John; Björn E Clausen; Esther von Stebut
Journal:  J Exp Med       Date:  2011-05-02       Impact factor: 14.307

Review 10.  A research agenda for helminth diseases of humans: the problem of helminthiases.

Authors:  Sara Lustigman; Roger K Prichard; Andrea Gazzinelli; Warwick N Grant; Boakye A Boatin; James S McCarthy; María-Gloria Basáñez
Journal:  PLoS Negl Trop Dis       Date:  2012-04-24
View more
  11 in total

Review 1.  Human innate lymphoid cells (ILCs) in filarial infections.

Authors:  S Bonne-Année; T B Nutman
Journal:  Parasite Immunol       Date:  2017-06-15       Impact factor: 2.280

2.  Functional Impairment of Murine Dendritic Cell Subsets following Infection with Infective Larval Stage 3 of Brugia malayi.

Authors:  Aditi Sharma; Pankaj Sharma; Achchhe Lal Vishwakarma; Mrigank Srivastava
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

Review 3.  Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis.

Authors:  Zhiwei Hu; Samira A Brooks; Valérian Dormoy; Chia-Wen Hsu; Hsue-Yin Hsu; Liang-Tzung Lin; Thierry Massfelder; W Kimryn Rathmell; Menghang Xia; Fahd Al-Mulla; Rabeah Al-Temaimi; Amedeo Amedei; Dustin G Brown; Kalan R Prudhomme; Annamaria Colacci; Roslida A Hamid; Chiara Mondello; Jayadev Raju; Elizabeth P Ryan; Jordan Woodrick; A Ivana Scovassi; Neetu Singh; Monica Vaccari; Rabindra Roy; Stefano Forte; Lorenzo Memeo; Hosni K Salem; Leroy Lowe; Lasse Jensen; William H Bisson; Nicole Kleinstreuer
Journal:  Carcinogenesis       Date:  2015-06       Impact factor: 4.944

4.  Identification of Genes Encoding Antimicrobial Proteins in Langerhans Cells.

Authors:  Aislyn Oulee; Feiyang Ma; Rosane M B Teles; Bruno J de Andrade Silva; Matteo Pellegrini; Eynav Klechevsky; Andrew N Harman; Jake W Rhodes; Robert L Modlin
Journal:  Front Immunol       Date:  2021-08-26       Impact factor: 8.786

Review 5.  Immunology of lymphatic filariasis.

Authors:  S Babu; T B Nutman
Journal:  Parasite Immunol       Date:  2014-08       Impact factor: 2.280

6.  Attempts to Image the Early Inflammatory Response during Infection with the Lymphatic Filarial Nematode Brugia pahangi in a Mouse Model.

Authors:  Elmarie Myburgh; Ryan Ritchie; Amy Goundry; Kerry O'Neill; Francesco Marchesi; Eileen Devaney
Journal:  PLoS One       Date:  2016-12-16       Impact factor: 3.240

7.  Differential immunomodulation in human monocytes versus macrophages by filarial cystatin.

Authors:  Gopinath Venugopal; Marion Mueller; Susanne Hartmann; Svenja Steinfelder
Journal:  PLoS One       Date:  2017-11-15       Impact factor: 3.240

8.  Mycobacteria induce TPL-2 mediated IL-10 in IL-4-generated alternatively activated macrophages.

Authors:  Soumya Chatterjee; Kawsar R Talaat; Emily E van Seventer; Carl G Feng; Alan L Scott; Anne Jedlicka; Amanda Dziedzic; Thomas B Nutman
Journal:  PLoS One       Date:  2017-06-28       Impact factor: 3.240

Review 9.  Group 2 Innate Lymphoid Cells (ILC2): Type 2 Immunity and Helminth Immunity.

Authors:  De'Broski R Herbert; Bonnie Douglas; Kelly Zullo
Journal:  Int J Mol Sci       Date:  2019-05-08       Impact factor: 5.923

10.  Transcriptome-wide analysis of filarial extract-primed human monocytes reveal changes in LPS-induced PTX3 expression levels.

Authors:  B C Buerfent; L Gölz; A Hofmann; H Rühl; W Stamminger; N Fricker; T Hess; J Oldenburg; M M Nöthen; J Schumacher; M P Hübner; A Hoerauf
Journal:  Sci Rep       Date:  2019-02-22       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.